JPRN-jRCT2080225026已完成3 期
A Phase 3, Randomized, Observer-blinded Study of JVC-001 Compared to Active-controlled in Healthy Japanese Children 1 Year of Age
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 840
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12month old 至 <= 23month old（—）
- 性别
- All
入选标准
- •Japanese healthy children of 12 months and older and younger than 24 months
排除标准
- •- Subjects with history of measles, mumps, or rubella infection
- •- Subjects with measles, mumps, or rubella infection
- •- Subjects with history of measles, mumps, or rubella virus vaccination
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 18.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 18.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-NLIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 17.1Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-SEIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 17.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-FRIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerEUCTR2014-000294-39-ATIncyte Corporation270
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced Pancreatic CancerAdvanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapyMedDRA version: 17.1Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2014-000294-39-DKIncyte Corporation86